Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
Sales of implants are set to fall sharply as non-urgent procedures are deferred.